2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Non-Biological Therapies, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Bleeding and Clotting, Platelet Disorders, Genetic Disorders, Immunology, Autoimmune Disorders, Infectious Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult
PAPER

3842 Prevalence, molecular associations, and prognostic impact of chronic kidney disease in chronic myelomonocytic leukemia

Abdullah Ramzan, MD, Clifford Csizmar, M.D., Ph.D.2, Abhishek Avinash Mangaonkar, MBBS3, Antoine N. Saliba, M.D.4, Hassan B Alkhateeb, M.D.5, Naseema Gangat, MBBS6, William Hogan, M.B., B.Ch.7, Kristen McCullough, PharmD8, Mithun Shah, MD, PhD9, Aref Al-Kali, M.D.10, Tariq Kewan, MD11, Aasiya Matin, MBBS12, Sandra M. Herrmann, MD13, Nelson Leung, MD14, Mariam Alexander, MD15, Mrinal M. Patnaik, MD, MBBS16
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Rochester, Minnesota, United States
10 Mayo Clinic, Rochester, Minnesota, United States
11 Mayo Clinic, Rochester, Minnesota, United States
12 Mayo Clinic, Rochester, Minnesota, United States
13 Mayo Clinic, Rochester, Minnesota, United States
14 Mayo Clinic, Rochester, Minnesota, United States
15 Mayo Clinic, Rochester, Minnesota, United States
16 Mayo Clinic, Rochester, Minnesota, United States
Background: Chronic kidney disease (CKD) is common among older adults and is associated with increased morbidity and mortality. Chronic Myelomonocytic Leukemia (CMML) frequently affects elderly patients with multiple comorbidities and has unique disease-related mechanisms of renal injury, including lysozyme nephropathy, monocytic infiltration, and myeloproliferative neoplasm (MPN) glomerulopathy (Natu et al. Kidney International 2024). Despite these observations, the prevalence, clinicopathologic associations, and prognostic significance of CKD in CMML remain poorly defined.

Methods: We performed a retrospective study of consecutive patients with WHO-defined CMML evaluated at Mayo Clinic. Baseline CKD was defined using estimated glomerular filtration rate (eGFR) at diagnosis and categorized according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria. Clinical characteristics, laboratory parameters, cytogenetic findings, and recurrent somatic mutations were compared according to CKD status. Overall survival (OS) was estimated using the Kaplan-Meier method and compared by log-rank testing. Cox proportional hazards regression evaluated the independent association between CKD and OS after adjustment for age, sex, cardiovascular comorbidities, and established CMML prognostic models.

Results: Among 361 evaluable patients, 241 (66.8%) were male, the median age was 71 years, 170 (47%) had myeloproliferative (MP) CMML versus 191 (53%) for myelodysplastic (MD) CMML. 222 (61%) had hypertension, 90 (25%) had diabetes mellitus (DM), and 120 (33%) were obese (body mass index > 30). 126 (35%) had KDIGO Stage 3 or higher CKD at CMML diagnosis, while 1 patient was on hemodialysis at diagnosis. Patients with CKD were older (median age 74 versus 70, p<0.0001) and had a higher prevalence of DM (33% versus 21%, p=0.024) and hypertension (77% versus 55%, p<0.001). There was no significant difference in obesity (p=0.16) or diagnosis of MP-CMML versus MD-CMML (p=0.11).  The baseline presence of CKD was associated with higher white blood cell (WBC) counts; median 14.1 x109/L (range 7.6-26.7) in the CKD group versus 11.4 x 109/L (range 6.38-20.75) in the no CKD group (p=0.036) and was not influenced by absolute monocyte counts (p=0.28), ASXL1 (p=0.26), RAS pathway mutations (NRAS, KRAS, CBL, PTPN11; p=0.76), or baseline elevated lysozyme levels (n=45 informative cases, p=0.234). Receiver operating curve analysis identified a WBC count >19.5 x 109/L as being associated with CKD. There were no significant differences in risk stratification between the 2 groups using the BLAST-Mol and CPSS-Mol risk stratification models.

Kidney biopsies were available in 13 patients and demonstrated lysozyme nephropathy (n=3), CMML-associated interstitial infiltration (n=2), MPN-glomerulopathy (n=1), and nonspecific chronic glomerular lesions (n=7).

After a median follow-up of 18.2 months, 240 deaths occurred. Median OS was significantly shorter among patients with CKD than those without CKD (23.3 vs 33.3 months; log-rank P=0.003). On univariable Cox regression, baseline CKD was associated with inferior OS (HR 1.48, 95% CI 1.14–1.92; P=0.003). CKD independently predicted inferior OS after adjustment for age and sex (HR 1.39, P=0.018), CPSS-Mol (HR 1.40, P=0.017), BLAST-Mol (HR 1.47, P=0.006), and cardiovascular comorbidities (DM + hypertension; HR 1.61, P=0.001).  In hematopoietic cell transplantation censored sensitivity analyses, CKD remained associated with inferior survival, although statistical significance was attenuated (HR 1.30, 95% CI 0.99–1.71; P=0.062). Assessment of proportional hazards suggested that the impact of CKD may vary over time, warranting future time-dependent analyses.

Conclusions: CKD is present in approximately one-third of patients with CMML and independently predicts inferior overall survival. The association between CKD and higher WBC counts suggests that proliferative disease biology may contribute to CMML-associated renal injury, particularly in susceptible patients. These findings raise the hypothesis that prolonged permissive leukocytosis may adversely affect long-term renal and clinical outcomes and support prospective studies evaluating whether earlier control of leukocytosis preserves kidney function and improves survival.



Abdullah Ramzan, MD: No relevant conflicts of interest to declare.